Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Endometrial Cancer
Clinical trial register · United States · industry-sponsored

Endometrial Cancer Trials in the USA, 2026

Every industry-sponsored study on the ClinicalTrials.gov registry that lists a US site and is open, about to open, active-but-closed, or enrolling by invitation. This deliberately excludes academic and other non-industry sponsors — the full US registry across all sponsors runs to over 22,000 recruiting studies alone.

Download CSV
Source: ClinicalTrials.gov. Complete coverage of the industry-sponsored slice — all 9144 matching records are in this view (non-industry sponsors are out of scope by design, not truncated). Synced 16 Oct 2026, 03:16 UTC
9144
Studies in scope
industry-sponsored, all four open statuses
4957
Recruiting now
open to new participants
2196
Lead sponsors
across recruiting studies
Top states
California 36 Florida 33 Illinois 19 Massachusetts 18 New York 18
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
AstraZeneca6 Whitehawk Therapeutics, Inc.2 Merck Sharp & Dohme LLC2 Xencor, Inc.2 MOMA Therapeutics1
State
California36 Florida33 Illinois19 Massachusetts18 New York18
All 40 states
Target enrolment
to

Endometrial Cancer trials in the USA

45 of 9144 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
US states
Start
Not yet open
MTX-531-001 Phase 1 Study in Advanced Solid Tumors
NCT07874880Solid Tumors (Phase 1), HNSCC, Endometrial Cancer, Her2-negative Metastatic Breast Cancer
MEKanistic Therapeutics, Inc.
Phase 1
71
California
2026-10-20
Not yet open
Pfizer
Phase 3
600
Florida, Minnesota, Nevada, Ohio, Oregon, Tennessee, Texas, Virginia
2026-10-09
Not yet open
Natera, Inc.
Not applicable
1,010
Alabama, California, Florida, Illinois, Minnesota, New York, North Carolina, Ohio
2026-10
Recruiting
Phase 1 Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of ARR-002 in Advanced or Metastatic Ovarian or Endometrial Cancer.
NCT07755436Ovarian Cancer, Endometrial Cancer, Platinum-resistant Ovarian Cancer (PROC), Metastatic Ovarian Cancer
ArriVent BioPharma, Inc.
Phase 1
180
Florida, Massachusetts, Tennessee, Texas, Virginia
2026-07-23
Recruiting
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
NCT07383506PIK3CA Mutations, Advanced Solid Tumors, Adult, Endometrial Cancer, HR Positive/HER-2 Negative Breast Cancer
Cogent Biosciences, Inc.
Phase 1
90
Arizona, California, Colorado, Florida, Massachusetts, Missouri, New Jersey, Tennessee
2026-07-23
Recruiting
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
NCT07524322Breast Cancer, Ovarian Cancer, Endometrial Cancer, PIK3CA Mutation
Regor Pharmaceuticals Inc.
Phase 1
63
California, Texas, Virginia
2026-06
Recruiting
A Phase 1 Study of the Safety and Tolerability of CTX-10726
NCT07419841Gastroesophageal Cancer (GC), Hepatocellular Carcinoma (HCC), Endometrial Cancer, Renal Cell Carcinoma (RCC)
Compass Therapeutics
Phase 1
70
Arizona, Florida, Minnesota, Nebraska, New York, Pennsylvania, South Carolina, Tennessee
2026-05-28
Recruiting
A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
NCT07470853PROC, Platinum Resistant Ovarian Cancer, Endometrial Cancer
DrugBevacizumab
Whitehawk Therapeutics, Inc.
Phase 1
265
Arkansas, California, Florida, Illinois, Michigan, New York, North Carolina, Ohio
2026-03-15
Active, closed
Endometrial Cancer Vaginal Fluid Specimen Collection Study
NCT07544680Abnormal Uterine Bleeding (AUB), Endometrial Cancer, Atypical Endometrial Hyperplasia, Endometrial Hyperplasia With Atypia
Exact Sciences Corporation
Observational
4,200
Florida, Maine, Tennessee, Texas
2026-03-10
Recruiting
Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors
NCT07444814Endometrial Cancer, Ovarian Cancer, Ovarian Cancer Metastatic, Ovarian Cancer Metastatic Recurrent
Whitehawk Therapeutics, Inc.
Phase 1
226
Arkansas, California, Illinois, Michigan, New Jersey, New York, Ohio, Texas
2025-12-19
Recruiting
Genmab
Phase 3
660
Alabama, Arizona, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-11-28
Recruiting
Daiichi Sankyo
Phase 3
710
Florida, Indiana, Louisiana, North Carolina, Ohio, South Dakota, Texas
2025-09-30
Recruiting
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
NCT07109726Breast Cancer, Endometrial Cancer, Ovarian Cancer, Lung Squamous Cell Carcinoma
DrugFulvestrant
Terremoto Biosciences Inc.
Phase 1/2
205
California, Florida, Illinois, Massachusetts, Minnesota, Missouri, Nebraska, North Carolina
2025-09-23
Recruiting
AstraZeneca
Phase 3
800
Arizona, California, District of Columbia, Florida, Hawaii, Illinois, Indiana, Maine
2025-08-01
Recruiting
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
NCT06974110Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
DrugIrinotecan
MOMA Therapeutics
Phase 1
132
Arizona, California, Florida, Michigan, Missouri, North Carolina, Oregon, Texas
2025-07-16
Recruiting
BioNTech SE
Phase 3
480
Connecticut, District of Columbia, Florida, Illinois, Louisiana, Nevada, New York, Ohio
2025-06-10
Recruiting
Merck Sharp & Dohme LLC
Phase 3
1,123
Alabama, Alaska, California, Connecticut, District of Columbia, Florida, Georgia, Illinois
2025-05-22
Recruiting
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
NCT06906341Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Neoplasms, Endometrial Cancer
DrugsNab-paclitaxel /m^2·Relacorilant·Bevacizumab
Corcept Therapeutics
Phase 2
270
Alabama, California, Florida, Minnesota, Missouri, New Mexico, Ohio, Oregon
2025-04-11
Recruiting
A Study of PHST001 in Advanced Solid Tumors
NCT06840886Advanced Solid Tumors, Ovarian Cancer, Endometrial Cancer, Cholangiocarcinoma
DrugsMIRV·Mirvetuximab Soravtansine·Adriamycin·Topotecan
Pheast Therapeutics
Phase 1
426
California, Colorado, Connecticut, Illinois, Massachusetts, Michigan, New York, North Carolina
2025-03-31
Recruiting
AstraZeneca
Phase 3
600
Arizona, Arkansas, California, Florida, Georgia, Hawaii, Illinois, Louisiana
2025-03-27
Recruiting
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
NCT06774963Ovarian Cancer, Breast Cancer, Endometrial Cancer, Biliary Tract Cancer
NextCure, Inc.
Phase 1
145
California, Kentucky, Massachusetts, Missouri, New Jersey, New York, Ohio, Pennsylvania
2025-01-07
Recruiting
Faeth Therapeutics
Phase 2
40
California, Florida, Maryland, Minnesota, New York, Ohio, Oregon, Pennsylvania
2024-12-12
Recruiting
Iovance Biotherapeutics, Inc.
Phase 2
60
Arizona, California, Florida, Georgia, Kentucky, Michigan, New York, Oklahoma
2024-10-29
Active, closed
Gilead Sciences
Phase 3
640
Arkansas, California, Colorado, Connecticut, Florida, Georgia, Illinois, Indiana
2024-08-28
Active, closed
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
NCT06533059Cancer, Breast Cancer, Endometrial Cancer, Metastatic Cancer
Alterome Therapeutics, Inc.
Phase 1
110
California, Colorado, Florida, Massachusetts, Missouri, Tennessee, Texas, Virginia
2024-08-22
Recruiting
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
NCT06515613Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
Context Therapeutics Inc.
Phase 1
156
Arkansas, California, Colorado, Massachusetts, Nebraska, New Jersey, New York, North Carolina
2024-07-10
Recruiting
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
NCT06276491Ovarian Cancer, Endometrial Cancer, Germ Cell Tumor, Testicular Germ Cell Tumor
DrugXmAb541
Xencor, Inc.
Phase 1
282
California, Florida, Georgia, Illinois, Indiana, Michigan, Minnesota, New Jersey
2024-04-04
Recruiting
Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors
NCT06218914Non-small Cell Lung Cancer, Colorectal Carcinoma, Pancreatic Ductal Adenocarcinoma, Endometrial Cancer
AstraZeneca
Phase 1
108
California, Florida, Illinois, Kansas, Massachusetts, Missouri, New York, Oregon
2024-03-22
Recruiting
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma
DrugT-Bren
SystImmune Inc.
Phase 1
280
Alabama, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Missouri
2024-02-09
Recruiting
Aadi Bioscience, Inc.
Phase 2
29
Arkansas, Florida, Nevada, New York, North Carolina, Oklahoma, Rhode Island, Texas
2023-12-28
Active, closed
Merck Sharp & Dohme LLC
Phase 3
710
Alabama, Alaska, Arizona, California, Connecticut, District of Columbia, Florida, Georgia
2023-12-06
Recruiting
Kartos Therapeutics, Inc.
Phase 2/3
268
California, Georgia, Illinois, Indiana, Maryland, Minnesota, Missouri, Nevada
2023-07-17
Recruiting
Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT05797168Ovarian Cancer, Lung Adenocarcinoma, Endometrial Cancer, Lung Squamous Cell Carcinoma
DrugsPalacaparib·Torvutatug samrotecan·Saruparib·Paraplatin
AstraZeneca
Phase 1/2
622
California, Colorado, Kentucky, Massachusetts, Michigan, Ohio, Oregon, Rhode Island
2023-06-05
Active, closed
Karyopharm Therapeutics Inc
Phase 3
257
Alabama, Arizona, Arkansas, California, Florida, Georgia, Illinois, Indiana
2023-04-18
Active, closed
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
NCT05527184Endometrial Cancer, High Grade Serous Adenocarcinoma of Ovary, Primary Peritoneal Carcinoma, Fallopian Tube Cancer
DrugIMGN151
AbbVie
Phase 1
256
Alabama, California, Colorado, Florida, Illinois, Massachusetts, Michigan, Mississippi
2023-01-11
Recruiting
AstraZeneca
Phase 2
454
California, Indiana, Kansas, Massachusetts, Michigan, New Jersey, New Mexico, New York
2022-09-06
Recruiting
BP1001-A in Patients With Advanced or Recurrent Solid Tumors
NCT04196257Solid Tumor, Adult, Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Endometrial Cancer
Bio-Path Holdings, Inc.
Phase 1
50
Maryland, Michigan, Texas
2022-08-19
Recruiting
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
NCT05377996Triple Negative Breast Cancer, Breast Cancer, Endometrial Cancer, Ovarian Cancer
Day One Biopharmaceuticals, Inc.
Phase 1/2
360
Arizona, California, Florida, Georgia, Illinois, Massachusetts, Michigan, Minnesota
2022-08-15
Active, closed
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT05032040Ovarian Cancer, Clear Cell Carcinoma, Endometrial Cancer, Cervical Carcinoma
Xencor, Inc.
Phase 2
170
Arizona, California, Colorado, Delaware, Florida, Georgia, Michigan, Nevada
2022-07-21
Recruiting
First in Human Study of TORL-1-23 in Participants With Advanced Cancer
NCT05103683Advanced Solid Tumor, Ovarian Cancer, Endometrial Cancer, NSCLC
DrugTORL-1-23
TORL Biotherapeutics, LLC
Phase 1
90
California, Kentucky, Minnesota, New York, Ohio, Texas, Virginia
2021-11-17
Recruiting
AstraZeneca
Phase 1/2
460
California, Louisiana, Maryland, Massachusetts, Missouri, New Mexico, New York, North Carolina
2021-10-18
Recruiting
Regeneron Pharmaceuticals
Phase 1/2
612
California, Florida, Illinois, Massachusetts, Michigan, New York, Ohio, Pennsylvania
2020-12-08
Active, closed
A Study of LY3484356 in Participants With Advanced or Metastatic Breast Cancer or Endometrial Cancer
NCT04188548Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer, Endometrial Cancer
DrugsImlunestrant·Alpelisib·Everolimus·Abemaciclib
Eli Lilly and Company
Phase 1
379
Arizona, Arkansas, California, Florida, Georgia, Indiana, Maryland, Massachusetts
2019-12-10
Active, closed
ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)
NCT04044859Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ), Gastric (Stomach) Cancer
USWM CT, LLC
Phase 1
120
Florida, Massachusetts, Missouri, New York, North Carolina, Oklahoma, Tennessee, Texas
2019-08-20
Active, closed
Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT03860272Advanced Cancer, Angiosarcoma, Colorectal Cancer Without Liver Metastases, Endometrial Cancer
DrugsBalstilimab·Botensilimab
Agenus Inc.
Phase 1
499
Arizona, California, Colorado, Connecticut, Florida, Massachusetts, New York, Oregon
2019-03-20
Rows per page Showing 1–45 of 45
1
Cite this view

Priya Life Science (2026). Clinical trial register: industry-sponsored studies with a US investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 16 October 2026. https://priyalifescience.com/clinical-trials-usa/condition/endometrial-cancer

Query this register directly
GET /api/trials?country=usa&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every industry-sponsored study on the registry that lists at least one investigative site in the US and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 9,144 studies in total at the last sync on 16 Oct 2026, 03:16 UTC. Academic and other non-industry sponsors are out of scope by design. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 45 of those studies listing the condition Endometrial Cancer.

How many Endometrial Cancer trials are recruiting in the US?

32 of the 45 studies on this page are recruiting new participants as of the 16 Oct 2026, 03:16 UTC sync. A further 3 have not yet opened recruitment, 10 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Endometrial Cancer), 45 studies
PhaseStudiesRecruitingShare
Phase 1211546.7%
Phase 310622.2%
Phase 26513.3%
Phase 1/25511.1%
Not applicable102.2%
Observational102.2%
Phase 2/3112.2%

Most active sponsors

Lead sponsors with the most studies (Endometrial Cancer)
Lead sponsorStudiesRecruiting
AstraZeneca66
Merck Sharp & Dohme LLC21
Whitehawk Therapeutics, Inc.22
Xencor, Inc.21
Aadi Bioscience, Inc.11
AbbVie10
Agenus Inc.10
Alterome Therapeutics, Inc.10
ArriVent BioPharma, Inc.11
Bio-Path Holdings, Inc.11

Top states

Top states (Endometrial Cancer), by number of studies with a site there
StateStudies
California36
Florida33
Illinois19
Massachusetts18
New York18
Michigan14
Arizona13
Georgia13
Ohio12
Texas12
Listing here is informational and not medical advice; eligibility is determined by each study team. Compare pay for the teams running these studies in the US Pharma Salary Guide, see who's behind them in the US Company Directory, or track approvals on the FDA Approvals Tracker. For Irish, UK and EU sites, see the Ireland, UK and EU registers.